Publications

CORRIGENDUM: Impact of the Covid-19 Pandemic on the Diagnosis of Tuberculosis in Brazil: Is the Who End Tb Strategy at Risk?(Front. Pharmacol., (2022), 13, (891711), 10.3389/Fphar.2022.891711)

AuthID
P-00X-904

Author(s)

Rosário Souza, MD

Silva da Paz, W

dos Santos Sales, VB

Hilario de Jesus, GF

dos Santos Tavares, D

Almeida Lima, SVM

Lopes Sousa, AF

Vieira de Melo, E

Feliciano do Carmo, R

Freire de Souza, CD

Bezerra Santos, M

Document Type

Correction

Year published

2022

Published

in Frontiers in Pharmacology, ISSN: 1663-9812

Volume: 13

Indexing

Scopus^®

Google Scholar^®

Publication Identifiers

DOI: 10.3389/fphar.2022.999301

Scopus: 2-s2.0-85138325377

Source Identifiers

ISSN: 1663-9812

Export Publication Metadata

Marked List

Add to Marked List

Citations

Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

CORE Conference

No information about CORE Rank

During the preprocessing phase, only publications of type 'Proceedings Paper' or 'Proceedings' are automatically processed to identify their CORE Rank.

TIP: If your publication's CORE Rank is missing, you can contact with your institutional manager to have the correct ranking manually added to the record.

Journal Factors

Oops! It looks like you don't have access to this content.

This section is restricted to uses with b-on access.

Info

At this moment we don't have any links to full text documens.

CORRIGENDUM: Impact of the Covid-19 Pandemic on the Diagnosis of Tuberculosis in Brazil: Is the Who End Tb Strategy at Risk?(Front. Pharmacol., (2022), 13, (891711), 10.3389/Fphar.2022.891711)

Useful Links

Get Help

Federated Authentication (Click on the image)

CORRIGENDUM: Impact of the Covid-19 Pandemic on the Diagnosis of Tuberculosis in Brazil: Is the Who End Tb Strategy at Risk?(Front. Pharmacol., (2022), 13, (891711), 10.3389/Fphar.2022.891711)

Useful Links

Get Help